Diego Felipe Ballen
@BallenDF
Followers
1K
Following
9K
Media
109
Statuses
3K
Oncólogo colombiano. Ayudo a los pacientes con cáncer a resolver algunos de sus problemas. #PrecisionOncology #GIOncology #BreastCancer Opiniones personales.
Bogotá D.C.
Joined August 2010
RT @JagomezR_MD: 🚨 Cáncer y corazón: el precio oculto de la supervivencia. Aquí👇 los 10 mensajes clave que todo médico debe conocer sobre….
0
94
0
RT @Erman_Akkus: 📣Durva-FLOT was added to NCCN guidelines of gastric and GEJ adenoca. ✅For PDL1 positive tumors, category 1.✅CPS or TAP.✅PD….
0
88
0
RT @chavarriagaj: #SCU25 In a crossfire debate, @LuisSalgadoS challenged the role of treating the primary & MDT in low-volume mHSPC:.📉 PF….
0
7
0
RT @Erman_Akkus: 🟠Management of locally advanced rectal cancer.@myESMO . ✅Excellent summary of key trials .✅Treatment recommendations based….
0
67
0
We should take MATTERHORN data with caution. KN-585 is a negative ITT trial with a mOS benefit of 16 m! In MAT almost all pts were PDL1 positive (TAP) and 1/3 GEJ. Can we use same treatment for diffuse distal GC? Do PDL1- patients benefit from it? MSI-H need all this treatment?.
📌 KEYNOTE-585 Final Analysis..🧑⚕️ Resectable GC/GEJ (~1000 pts).💊 Pembro+CT vs placebo+CT.Main: OS 71.8 vs 55.7 mo (HR 0.86), EFS HR 0.81.FLOT: OS NR vs 55.7 mo (HR 0.86), EFS HR 0.80.🧬 ↑pathCR | ⚖️ G≥3 AEs similar | 🙂 QoL preserved.❓Why MATTERHORN
0
0
4
RT @Betzabe100: Last week we had a beautiful LATAM symposium! beautiful time and discussion about mCRC and friendship, thanks to all of yo….
0
8
0
RT @Dr_ElvinaA: France’s health authority has decided not to reimburse adjuvant ribociclib in early HR+/HER2– breast cancer, citing limited….
0
38
0
RT @elfasaco: Con gran satisfacción y orgullo,felicitamos al Dr.@OssianFuentes por la culminación de su especialización en Cirugía Oncológi….
0
3
0
RT @brian_rini: Final KN426 clinical and translational data published @NatureMedicine. The balance of inflammation / angiogenesis impacts….
nature.com
Nature Medicine - Five-year follow-up and prespecified exploratory biomarker analysis from the phase 3 KEYNOTE-426 trial show that pembrolizumab plus axitinib compared to sunitinib as first-line...
0
39
0
RT @NiuSanford: This is a great read. D-FLOT approved for all gastric/GEJ adeno (at least in US), but which subset of patients appear to b….
0
19
0
Keynote Lecture por @ClaraMontagut que nos ha ayudado a entender el valioso rol de la biopsia líquida en cáncer colorrectal. Gracias a la @achoHematoYOnco por esta excelente edición del simposio de Oncología Gastrointestinal. #ACHOGI2025 #TodosSomosACHO
1
7
28
RT @Onco_Cifu88: Grateful to join the first meeting of @achoHematoYOnco Young Oncologists Group 🇨🇴.A space to shape opportunities, promote….
0
3
0
RT @ESMO_Open: CDX2 expression as a predictive and prognostic biomarker of 5-FU response in cancer of unknown primary in @ESMO_Open. Higher….
0
32
0
RT @DrYukselUrun: Updated results from KEYNOTE-B61:.First-line pembrolizumab + lenvatinib in advanced non-clear-cell RCC shows:.✅ ORR 51%.✅….
0
45
0
RT @Onco_Cifu88: 🚨 Common sense in HCC trials:.Is PFS always a meaningful endpoint?.Not really. If progression-free survival doesn’t transl….
0
11
0
RT @INCancerologia: En el INC, se realizó un nuevo estudio comparando ambas técnicas en hepatectomías, usando el Textbook Outcome (TOLS) co….
0
6
0
RT @SuyogCancer: 🚨 GI Cancer Mortality to Double by 2050📊 ESMO GI 2025 shows sharp rise in deaths due to:.🔹 Colorectal: +103%.🔹 Pancreatic:….
0
63
0
